SecBot SecBot
DEFA14A ·Filed Jun 1, 2026

OTLK

Outlook Therapeutics, Inc.
BEARISH
Impact 6/10
Horizondays Processed5mo ago SEC0001140361-26-023585
Proxy solicitation materials
Actionable Insight ▼ Bearish

The 130.8% increase in authorized shares and reverse split authorization are strong bearish signals of impending dilution and potential Nasdaq delisting risk. Monitor for the actual reverse split ratio and timing of warrant exercises. The April 2026 registered direct offering warrants alone could add 18.4M+ shares of dilution. Consider short positioning or puts ahead of the July 16 vote.

DirectionBearish
Confidencehigh
Horizondays

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.8140
T+0 close · Jun 1, 2026 · via day close
Latest settled
−23.43%
T+60 · $0.6233
Vs SPY
−24.54%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 2 $0.8140entry
  2. T+1 · 6mo ago −0.52%α +0.18% · $0.8098
  3. T+5 · 5mo ago −13.39%α −10.43% · $0.7050
  4. T+20 · 5mo ago +80.59%α +82.15% · $1.47
  5. T+60 · 3mo ago −23.43%α −24.54% · $0.6233
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Outlook Therapeutics filed DEFA14A definitive additional proxy materials for its July 16, 2026 Special Meeting. The board recommends voting FOR: (1a) issuance of up to 16,129,033 shares underlying Private Placement Warrants and up to 2,258,064 shares underlying Placement Agent Warrants from an April 2026 registered direct offering; (1b) issuance of up to 2,142,854 shares underlying previously issued common warrants; (2) increasing authorized common shares from 260M to 600M; and (3) a reverse stock split at a ratio between 1:10 and 1:50 at the board's discretion. The massive authorized share increase and reverse split authorization signal the company is preparing for significant future dilution and potential Nasdaq compliance needs.

Key Financial Metrics

Meeting
2026-07-16

Key Facts

  • Special Meeting scheduled for July 16, 2026; vote by July 15, 2026
  • Proposal 1a: Approve issuance of up to 16,129,033 shares underlying Private Placement Warrants and up to 2,258,064 shares underlying Placement Agent Warrants from April 2026 offering
  • Proposal 1b: Approve issuance of up to 2,142,854 shares underlying previously issued common warrants
  • Proposal 2: Increase authorized common shares from 260,000,000 to 600,000,000 (a 130.8% increase)
  • Proposal 3: Authorize reverse stock split at ratio of 1-for-10 to 1-for-50, at board's discretion
  • Board recommends FOR all proposals
  • Market cap is $88M with 78% analyst bullish rating

Financial Impact

Authorized share count increasing by 340M shares (130.8% increase) signals massive potential dilution. Combined warrant-related issuances could add up to 20.5M+ new shares. Reverse split authorization (1:10 to 1:50) indicates Nasdaq compliance concerns.

dilutionauthorized sharesshare count

Risk Factors

  • Massive dilution from authorized share increase (260M to 600M shares)
  • Reverse stock split signals potential Nasdaq non-compliance
  • Warrant exercises from April 2026 offering could further dilute existing shareholders
  • Low market cap ($88M) makes dilution impact more severe

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
78% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001140361-26-023585
Document: 0001140361-26-023585-index-headers.html0001140361-26-023585
Document: 0001140361-26-023585-index.html0001140361-26-023585
Document: 0001140361-26-023585.txt0001140361-26-023585

Track record

37 reports on OTLK

Performance horizon

12 of 22 bullish or bearish reports moved the stock their way by T+5. Best: +306.25% at T+20 after the May 26, 2026 report. 17 of 22 went positive at some point.

Filters
  1. Oct 13, 20264w ago SC 13G Neutral 4/10 Entry $0.5638 to $0.5200 Now $0.3960 −29.76% ▼ −7.77% −6.62% vs SPY
  2. Oct 6, 20265w ago Press Release Neutral 3/10 Entry $0.5720 to $0.5638 Now $0.3960 −30.77% ▼ −1.43% −1.29% vs SPY
  3. Sep 18, 20268w ago 8-K Neutral 3/10 Entry $0.6863 to $0.6211 Now $0.3960 −42.30% ▼ −9.50% −8.48% vs SPY
  4. Aug 14, 202613w ago 8-K Bearish 6/10 Entry $0.7564 to $0.6472 Now $0.3960 +47.65% ▲ +14.44% +13.07% vs SPY
  5. Aug 14, 202613w ago 424B5 Bearish 7/10 Entry $0.7564 to $0.6472 Now $0.3960 +47.65% ▲ +14.44% +13.07% vs SPY
  6. Aug 14, 202613w ago 8-K Bearish 6/10 No price data
  7. Aug 14, 202613w ago Press Release Mixed 7/10 Entry $0.7564 to $0.6472 Now $0.3960 −47.65% ▼ −14.44% −13.07% vs SPY
  8. Aug 12, 202613w ago Press Release Bearish 7/10 Entry $0.8888 to $0.6763 Now $0.3960 +55.45% ▲ +23.91% +21.94% vs SPY
  9. Aug 12, 202613w ago 8-K Bearish 7/10 Entry $0.8888 to $0.6763 Now $0.3960 +55.45% ▲ +23.91% +21.94% vs SPY
  10. Jul 24, 202616w ago 8-K Bullish 8/10 Entry $1.07 to $0.9766 Now $0.3960 −62.82% ▼ −8.30% −9.37% vs SPY
Showing 10 of 37

US Market Status

Market Closed · Opens in 6h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 1, 2026